What does Genvoya® contain?

What does Genvoya® contain?

• A. elvitegravir/cobicistat/emtricitabine/TAF
• B. dolutegravir + rilpivirine
• C. rilpivirine + tenofovir + emtricitabine
• D. emtricitabine + TAF

Answer: (A)

Genvoya® is a comprehensive antiretroviral medication used in the treatment of HIV-1 infection, and it is essential to know its specific components for effective treatment. The correct answer includes elvitegravir, a potent integrase inhibitor that helps prevent the virus from integrating into the host DNA. Additionally, Genvoya® contains cobicistat, which acts as a booster for elvitegravir, enhancing its efficacy by increasing its concentration in the bloodstream. Emtricitabine and tenofovir alafenamide (TAF), both nucleoside reverse transcriptase inhibitors, work in conjunction to block viral replication. This combination targets multiple stages of the HIV lifecycle, making Genvoya® a highly effective option for individuals living with HIV. The presence of TAF is particularly notable as it has a better safety profile and less bone density impact compared to older tenofovir formulations, illustrating the careful consideration of patient health in HIV treatment options.

Genvoya® is a comprehensive antiretroviral medication used in the treatment of HIV-1 infection, and it is essential to know its specific components for effective treatment. The correct answer includes elvitegravir, a potent integrase inhibitor that helps prevent the virus from integrating into the host DNA. Additionally, Genvoya® contains cobicistat, which acts as a booster for elvitegravir, enhancing its efficacy by increasing its concentration in the bloodstream. Emtricitabine and tenofovir alafenamide (TAF), both nucleoside reverse transcriptase inhibitors, work in conjunction to block viral replication. This combination targets multiple stages of the HIV lifecycle, making Genvoya® a highly effective option for individuals living with HIV. The presence of TAF is particularly notable as it has a better safety profile and less bone density impact compared to older tenofovir formulations, illustrating the careful consideration of patient health in HIV treatment options.